Glucose monitor could spot diabetes risk after pregnancy

NCT ID NCT07034261

Not yet recruiting Knowledge-focused Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test whether a continuous glucose monitor (CGM) worn for 14 days after childbirth can predict which women with a history of gestational diabetes are at risk for developing type 2 diabetes. Fifty participants will wear a blinded CGM device and then take a standard oral glucose tolerance test 4-12 weeks after delivery. The goal is to see if the CGM data can replace or improve upon the standard test for detecting postpartum blood sugar problems.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Blinded Continuous Glucose Monitoring Device
What this could lead to: If successful, this could show that a simple 14-day glucose monitor can identify women at risk for type 2 diabetes after gestational diabetes, potentially leading to earlier detection and prevention.
What could go wrong: This is a small, early-stage study (50 participants) that is not yet recruiting. It only measures how well the monitor predicts results of a standard test, not whether it improves health outcomes. The device is blinded, so participants cannot see their own glucose levels during the study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GESTATIONAL DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gestational diabetes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GESTATIONAL DIABETES

More trials for these conditions

Other studies related to the condition(s) this trial covers.